Astral share price drops 10% on chemicals demerger

What triggered the fall in Astral shares

Astral Ltd shares came under sharp selling pressure on Monday after the company approved a demerger of its chemicals business into a separately listed entity. On the BSE, the stock declined as much as 9.91% to ₹1,339.00. At 1:00 PM, Astral was trading 8.56% lower at ₹1,359.00 on the BSE.

On the NSE, the stock opened 4.7% lower at ₹1,417 and slipped to an intraday low of ₹1,385 in morning deals. As of 9:50 AM, it was down 6.2% at ₹1,394. Another data point during the session showed the scrip falling 6.85% to ₹1,392.70 at 9:40 AM, even as the Nifty 50 was up 0.07%.

What the board approved: demerger into Astral Chemie

Astral said its Board of Directors approved a plan to demerge its chemicals business undertaking on a going concern basis. The chemicals business includes adhesives, paints and speciality chemicals.

Under the scheme described in the coverage, Astral’s chemicals business is to be transferred to a new company, Astral Chemie Limited (earlier known as Astral Coatings Private Limited), which is expected to be listed independently on the NSE and BSE, subject to approvals. The board approval followed consideration of recommendations from the audit committee and independent directors.

In a separate development highlighted in the same news flow, Astral was also reported to have approved the amalgamation of its wholly owned subsidiary, Al-Aziz Plastics.

Shareholder entitlement and listing timeline

As per the details reported, Astral shareholders are expected to receive shares in the demerged entity in a 1:1 ratio. That means investors holding one share of Astral Ltd would receive one share of Astral Chemie, once the process is completed.

The timeline is expected to be lengthy. The demerger would require approvals from the National Company Law Tribunal (NCLT), SEBI, NSE, BSE and other regulatory bodies, along with approvals from shareholders and creditors. The process could take around 12 months or more, according to the reported commentary.

Why brokerages see near-term pressure

Equirus Securities said the demerger could create a near-term overhang on Astral’s stock performance as investors try to assess what valuation multiples each business could command after separate listing. The same concern was echoed in other reports that highlighted uncertainty around how investors will split value between the remaining operations and the demerged company.

JPMorgan, in a separate note mentioned in the reports, downgraded Astral to ‘Neutral’ from ‘Overweight’ after the announcement. It said that while valuation impact may be limited, uncertainties around future cost allocation and cash flows remain. JPMorgan also flagged near-term pressure from declining domestic PVC prices, which could lead to inventory losses and channel destocking.

CLSA took a different view, saying the demerger is unlikely to have a meaningful impact on the stock in the near term, while adding that sustained growth and margin improvement in the chemicals business could drive any future rerating.

Brokerage calls and target prices: what changed

Despite the stock fall, several brokerages reiterated positive ratings, although some reduced target prices.

Equirus Securities maintained a ‘Long’ rating with a June 2027 target price of ₹1,980 per share. The brokerage said this implied an upside potential of over 33% from Thursday’s closing price. Another report referenced a previous close of ₹1,487 and stated the target implies an upside of 33% from that level.

ICICI Securities said it tweaked estimates and remained constructive on Astral, retaining a ‘Buy’ rating while cutting its March 2027 target to ₹1,738 from ₹1,805. ICICI also said the demerger is likely to result in greater disclosures from both businesses, enabling investors to value each business better.

JM Financial maintained an ‘ADD’ rating with a target of ₹1,600, and said key aspects to monitor for Astral Chemie after the demerger include funding for growth initiatives, profitability improvement and navigating competitive pressures.

Antique maintained a ‘Buy’ rating with a target price of ₹1,630, based on a PE multiple of 50x FY28 EPS. Investec maintained a ‘Buy’ rating with a target of ₹1,710. CLSA retained ‘Hold’ with a target of ₹1,475.

Key numbers at a glance

Market impact: why restructuring news moves the stock

The immediate market reaction suggests investors are factoring in execution risk and a waiting period before value discovery can happen through separate listings. With the listing and regulatory approvals potentially taking 12 months or more, the stock can remain sensitive to changing expectations on segment profitability, cost allocation, and capital needs.

The reported analyst commentary also shows that the market is trying to evaluate two questions at once. First, what valuation the chemicals business could command after listing as Astral Chemie. Second, how the remaining Paints and Adhesives segment will grow, with one report flagging concerns that the remaining business could be relatively sub-scale.

Analysis: what to track as the demerger process plays out

Based on the reported brokerage notes, the core variables for investors are disclosures, segment-level profitability and the mechanics of separation. ICICI’s note highlights the importance of greater disclosures post-demerger, which can reduce ambiguity in segment performance and make valuation more transparent.

JM Financial’s focus areas for Astral Chemie point to what can change once the chemicals entity has its own balance sheet: funding for growth initiatives, profitability improvement, and competitive pressures. Meanwhile, JPMorgan’s caution on PVC prices and potential inventory and channel dynamics shows how near-term operating factors can still influence sentiment, even when the headline event is corporate restructuring.

Conclusion

Astral shares fell sharply on Monday as investors reacted to the board-approved demerger of its chemicals business into Astral Chemie, with the stock hitting multiple intraday lows across exchanges. Brokerages offered mixed near-term views, ranging from concerns about an overhang to calls that the demerger may not materially change the stock in the near term.

The next milestones are regulatory clearances from NCLT and market regulators, along with shareholder and creditor approvals, before Astral Chemie can be listed and the 1:1 share entitlement can be implemented.